Trending menu:
The top indication in both India and China is pain, so clinical trial benchmarking for industry-sponsored trials was performed using the Feasibility Planner tool on GlobalData’s Pharma Intelligence Center.
Eli Lilly published results from IXORA-R, its Phase IV head-to-head psoriasis trial showing that Taltz (ixekizumab) is superior to Tremfya.
A Phase I trial conducted at Imperial College London reported positive results for CTH522, a potential chlamydia vaccine.
Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has so far enrolled seven out of its nine-patient target as of three to four weeks ago, a...
While Cassiopea’s Winlevi (clascoterone) is likely to be FDA approved in moderate-to-severe acne, it is at risk of diminishing clinician/patient interest following initially optimistic early uptake, experts said. The market...
Last week, AstraZeneca announced that its combination of Imfinzi (durvalumab) and the experimental drug tremelimumab failed to meet its primary endpoint of improving overall survival when compared to the standard...
GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates between January 1, 2009 and August 28, 2019.
Biologics for dementia is increasing within a therapy pipeline that has traditionally been all small molecules, the data show.
Of the 38 pipeline products that are currently in development stages, AAV-based delivery platforms account for 45% of these products.
This key finding has shaped the future direction for the drug as Mologen AG has confirmed that it will only pursue combination studies.
